Treatment with
sorafenib prolongs both the median survival and time to progression by nearly 3 months in patients with advanced
hepatocellular carcinoma. Although the effects of combining
sorafenib therapy with other anticancer treatment modalities have not been clarified, combination treatment is strongly expected to be beneficial. We report the case of a 50-year-old man who exhibited a partial response and portal vein
thrombosis (PVT) revascularization after
sorafenib combined with hepatic arterial infusion
chemotherapy (HAIC). He exhibited a decrease in
tumor size and PVT after 2 months of
sorafenib monotherapy. However, no additional response was seen during the subsequent 2 months. To achieve a better
tumor response, we combined HAIC with
sorafenib. Daily
cisplatin (7 mg/m(2) on days 1-5) and
5-fluorouracil (170 mg/m(2) on days 1-5) were infused repeatedly every 4 weeks, and the
sorafenib prescription was modified. After four cycles of combined
therapy, both the
tumor size and PVT were much improved and exhibited partial response.